UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 419

Sortiert nach

Ovarian suppression using luteinizing hormone-releasing hormone agonists during chemotherapy to preserve ovarian function and fertility of breast cancer patients: a meta-analysis of randomized studies

Annals of oncology, 2015-12, Vol.26 (12), p.2408-2419

2015

Link zum Volltext

Verfügbarkeit prüfen

Management of anaemia and iron deficiency in patients with cancer: ESMO Clinical Practice Guidelines

Annals of oncology, 2018-10, Vol.29 (Supplement_4), p.iv96-iv110

2018

Link zum Volltext

Verfügbarkeit prüfen

Management of anaemia and iron deficiency in patients with cancer: ESMO Clinical Practice Guidelines

Annals of oncology, 2018-10, Vol.29 (Supplement_4), p.iv271-iv271

2018

Link zum Volltext

Verfügbarkeit prüfen

The predictive and prognostic role of single nucleotide gene variants of PD-1 and PD-L1 in patients with advanced melanoma treated with PD-1 inhibitors

Immuno-oncology technology, 2023-12, Vol.20, p.100408-100408, Article 100408

2023

Link zum Volltext

Verfügbarkeit prüfen

HER2-positive metastatic breast cancer: A changing scenario

Critical reviews in oncology/hematology, 2015-07, Vol.95 (1), p.78-87

2015

Link zum Volltext

Verfügbarkeit prüfen

Safety and efficacy outcomes with erythropoiesis-stimulating agents in patients with breast cancer: a meta-analysis

Annals of oncology, 2015-04, Vol.26 (4), p.688-695

2015

Link zum Volltext

Verfügbarkeit prüfen

Corrections to “Management of anaemia and iron deficiency in patients with cancer: ESMO Clinical Practice Guidelines”

Annals of oncology, 2018-10, Vol.29, p.iv271-iv271

2018

Link zum Volltext

Verfügbarkeit prüfen

1517 Emergency department as place of end-of-life care and death in cancer patients

European journal of cancer (1990), 2015-09, Vol.51, p.S209-S210

2015

Link zum Volltext

Verfügbarkeit prüfen

Concurrent versus sequential adjuvant chemo-endocrine therapy in hormone-receptor positive early stage breast cancer patients: a systematic review and meta-analysis

Breast (Edinburgh), 2017-06, Vol.33, p.104-108

2017

Link zum Volltext

Verfügbarkeit prüfen

Fulvestrant (FUL) as first-line therapy in HR+ve, HER2-ve advanced breast cancer (ABC) patients (pts): when clinical practice comes earlier than clinical trials. Results from the GIM-13 AMBRA study

Annals of oncology, 2017-10, Vol.28 Suppl 6, p.vi32

2017

Link zum Volltext

Verfügbarkeit prüfen

5194 POSTER Is the 21-gene Breast Cancer Test (Oncotype DX®) Good Value for Money?

European journal of cancer (1990), 2011, Vol.47, p.S388-S388

2011

Link zum Volltext

Verfügbarkeit prüfen

Reply to letter to the editor ‘Primum non nocere’ by Templeton and Šeruga

Annals of oncology, 2015-10, Vol.26 (10), p.2198-2199

2015

Link zum Volltext

Verfügbarkeit prüfen

Neuromuscular and cardiac adverse events associated with immune checkpoint inhibitors: pooled analysis of individual cases from multiple institutions and literature

ESMO open, 2023-02, Vol.8 (1), p.100791-100791, Article 100791

2023

Link zum Volltext

Verfügbarkeit prüfen

Pathological and molecular characteristics distinguishing contralateral metastatic from new primary breast cancer

Annals of oncology, 2010-06, Vol.21 (6), p.1237-1242

2010

Link zum Volltext

Verfügbarkeit prüfen

First line chemotherapy of metastatic breast cancer

Annals of oncology, 2006-05, Vol.17 (suppl-5), p.v165-v168

2006

Link zum Volltext

Verfügbarkeit prüfen

1957 Ovarian suppression with luteinizing hormone-releasing hormone agonists during chemotherapy as a strategy to preserve ovarian function and fertility in breast cancer patients: A systematic review and meta-analysis of randomized studies

European journal of cancer (1990), 2015-09, Vol.51, p.S318-S319

2015

Link zum Volltext

Verfügbarkeit prüfen

Hormonotherapy of advanced prostate cancer

Annals of oncology, 2005-05, Vol.16 (suppl-4), p.iv80-iv84

2005

Link zum Volltext

Verfügbarkeit prüfen

1863 First line trastuzumab- or lapatinib-based therapy in her2-positive metastatic breast cancer patients after prior (neo)adjuvant trastuzumab

European journal of cancer (1990), 2015-09, Vol.51, p.S286-S286

2015

Link zum Volltext

Verfügbarkeit prüfen

A prospective observational study to evaluate G-CSF usage in patients with solid tumors receiving myelosuppressive chemotherapy in Italian clinical oncology practice

Medical oncology (Northwood, London, England), 2014, Vol.31 (1), p.797-797, Article 797

2014

Link zum Volltext

Verfügbarkeit prüfen

Breast cancer in elderly women: a different reality? Results from the NORA study

Annals of oncology, 2007-06, Vol.18 (6), p.991-996

2007

Link zum Volltext

Verfügbarkeit prüfen

Letrozole withdrawal response in locally advanced breast cancer

Annals of oncology, 2011-08, Vol.22 (8), p.1927-1928

2011

Link zum Volltext

Verfügbarkeit prüfen

Residual Risk of Relapse: a Systematic Review and a Consensus Project on Unmet needs for HER2-positive non Metastatic Breast Cancer Patients

European journal of cancer (1990), 2022-11, Vol.175, p.S57-S58

2022

Link zum Volltext

Verfügbarkeit prüfen

OR30 Prospective study of fertility preservation strategies in young early breast cancer patients: the PREFER (pregnancy and fertility) trial

Breast (Edinburgh), 2014-11, Vol.23, p.S12-S12

2014

Link zum Volltext

Verfügbarkeit prüfen

The relevance of stable disease (SD) as a surrogate end-point in advanced non-small cell lung cancer (NSCLC) patients treated with erlotinib (E) as the second/third line

Lung cancer (Amsterdam, Netherlands), 2012-06, Vol.77, p.S30-S31

2012

Link zum Volltext

Verfügbarkeit prüfen

183 An Italian Cost-effectiveness Analysis of Paclitaxel Albumin (nab Paclitaxel) Vs Solvent-based Paclitaxel for Metastatic Breast Cancer Patients – the CONSTANZA Study

European journal of cancer (1990), 2012-03, Vol.48, p.S93-S93

2012

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 419

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(336)
Mit Volltextzugriff
(352)

Publikationsform

Sprache

Erscheinungsjahr

n.n

Thema

Science & Technology
(183)
Life Sciences & Biomedicine
(164)
Humans
(157)
Female
(127)
Oncology
(110)
Middle Aged
(105)
Biological And Medical Sciences
(98)
Medical Sciences
(85)
Aged
(84)
Adult
(77)
Male
(72)
Breast Neoplasms - Drug Therapy
(67)
Pharmacology. Drug Treatments
(63)
Antineoplastic Combined Chemotherapy Protocols - Therapeutic Use
(62)
Antineoplastic Agents
(53)
Chemotherapy
(49)
Animals
(38)
Antineoplastic Combined Chemotherapy Protocols - Adverse Effects
(34)
Breast Neoplasms - Pathology
(32)
Rats
(31)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Ovarian suppression using luteinizing hormone-releasing hormone agonists during chemotherapy to preserve ovarian function and fertility of breast cancer patients: a meta-analysis of randomized studies

Management of anaemia and iron deficiency in patients with cancer: ESMO Clinical Practice Guidelines

Management of anaemia and iron deficiency in patients with cancer: ESMO Clinical Practice Guidelines

The predictive and prognostic role of single nucleotide gene variants of PD-1 and PD-L1 in patients with advanced melanoma treated with PD-1 inhibitors

HER2-positive metastatic breast cancer: A changing scenario

Safety and efficacy outcomes with erythropoiesis-stimulating agents in patients with breast cancer: a meta-analysis

Corrections to “Management of anaemia and iron deficiency in patients with cancer: ESMO Clinical Practice Guidelines”

1517 Emergency department as place of end-of-life care and death in cancer patients

Concurrent versus sequential adjuvant chemo-endocrine therapy in hormone-receptor positive early stage breast cancer patients: a systematic review and meta-analysis

Fulvestrant (FUL) as first-line therapy in HR+ve, HER2-ve advanced breast cancer (ABC) patients (pts): when clinical practice comes earlier than clinical trials. Results from the GIM-13 AMBRA study

5194 POSTER Is the 21-gene Breast Cancer Test (Oncotype DX®) Good Value for Money?

Reply to letter to the editor ‘Primum non nocere’ by Templeton and Šeruga

Neuromuscular and cardiac adverse events associated with immune checkpoint inhibitors: pooled analysis of individual cases from multiple institutions and literature

Pathological and molecular characteristics distinguishing contralateral metastatic from new primary breast cancer

First line chemotherapy of metastatic breast cancer

1957 Ovarian suppression with luteinizing hormone-releasing hormone agonists during chemotherapy as a strategy to preserve ovarian function and fertility in breast cancer patients: A systematic review and meta-analysis of randomized studies

Hormonotherapy of advanced prostate cancer

1863 First line trastuzumab- or lapatinib-based therapy in her2-positive metastatic breast cancer patients after prior (neo)adjuvant trastuzumab

A prospective observational study to evaluate G-CSF usage in patients with solid tumors receiving myelosuppressive chemotherapy in Italian clinical oncology practice

Breast cancer in elderly women: a different reality? Results from the NORA study

Letrozole withdrawal response in locally advanced breast cancer

Residual Risk of Relapse: a Systematic Review and a Consensus Project on Unmet needs for HER2-positive non Metastatic Breast Cancer Patients

OR30 Prospective study of fertility preservation strategies in young early breast cancer patients: the PREFER (pregnancy and fertility) trial

The relevance of stable disease (SD) as a surrogate end-point in advanced non-small cell lung cancer (NSCLC) patients treated with erlotinib (E) as the second/third line

183 An Italian Cost-effectiveness Analysis of Paclitaxel Albumin (nab Paclitaxel) Vs Solvent-based Paclitaxel for Metastatic Breast Cancer Patients – the CONSTANZA Study

Suchergebnisse filtern